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TOF     time of flight 
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Introduction 
I. Galactosylceramide Background 
In 1993, Koezuka and coworkers were researching marine natural products with anti-tumor 
activities at the Kirin Brewery, which led to the discovery of agelasphin (e.g. agelasphin 9b).  Research1 
on these natural products led to the creation of the KRN7000 (Figure 1). 
 
Figure 1: Structures of Agelasphin 9b and KRN7000 
 KRN7000 has been reported to stimulate NKT cells through its presentation by the CD1d 
protein. This stimulatory pathway may have potential for the treatment of tumors,2-3 infectious diseases,4-5 
and autoimmune conditions6-7.  Further studies involving alterations to this molecule are being 
investigated to observe how differences in glycolipid functionality alter immune responses. In the 
following paragraphs the structure and bioactivity of some of the glycolipids related to the goals of this 
thesis will be discussed.  
A. Composition Of A Galactosylceramide 
Generally, a galactosyl ceramide (a type of glycolipid) (Figure 2) is made up of a galactosyl 
moiety connected to a ceramide by what is known as a glycosidic bond. The ceramide consists of two 
hydrophobic lipid chains, one an amide acyl chain and the other a sphinganine, either of which can vary 
based on chain length, branching, or functional groups attached.  In the next section the influence of some 
glycolipids on the immune system will be presented.  
 
 Figure 2: General Structure of Galactosylceramides 
B. Immunomodulation 
Glycolipids have been shown to increase immunoactivity by interacting with the immune systems 
lymphocytes.8 Lymphocytes are white blood cells that serve various functions in the immune system. 
They are also related to adaptive immunity (immunity that develops as we age), as opposed to innate 
immunity (basic immunity that responds immediately but non-specifically to infections and pathogens).9 
The two major classes of lymphocytes are distinguished by cells which grow independently of the thymus 
(B cells) and that grow inside the thymus (T cells). Natural Killer T-lymphocytes (NKT cells) are a subset 
of lymphocytes that have T-cell receptors located on their surface.9 The glycolipid’s alkyl chains are 
utilized by binding to the CD1d protein of an antigen presenting cell through crevice-like tunnels. Once 
bound, the exposed sugar head of the glycolipid interacts with the T-cell receptor of the NKT cell. 
Interaction between the T-cell receptor and glycolipid causes the release of cytokines from the NKT 
cells.10 There are two groups of cytokines, T helper 1 (Th1) and T helper 2 (Th2), categorized based on 
their response upon release. Cytokines like interferon-γ (IFN- γ) and interleukin-2 (IL-2) exhibit an 
inflammatory response (Th1) associated with controlling bacterial, parasitic and viral infections as well as 
tumors. Interleukin-4 (IL-4) and IL-10 are examples of two cytokines responsible for an 
immunomodulatory response (Th2), which has been known to ameliorate autoimmune diseases, such as 
multiple sclerosis, lupus, rheumatoid arthritis, and type I diabetes.10 In the next section the research 
leading to the discovery of KRN7000 and its biological activity will be discussed. 
 II. Discovery Of KRN7000 
In 1993, Koezuka and coworkers were investigating marine natural products for bioactivity and 
came across the agelasphins, in particular, agelasphin 9b (extracted from the sponge Agelas Mauritianus) 
(Figure 1). The interestingly rare feature about these agelasphins was their α-glycosidic bonds, as opposed 
to the β-glycosidic bonds found in more advanced organisms. Around this time it was also discovered that 
glycolipids cause lymphocyte cell proliferation. Further studies11 of the bioactivity led to structural 
determination that indicated the C4 hydroxyl group as nonessential for bioactivity and the C3 hydroxyl 
group as necessary for T-cell stimulation. Alteration of the lipid chains led to the creation of the 
galactosylceramide KRN7000.  
KRN7000 is now widely known for its interaction with NKT cells leading to the release of both 
Th1 and Th2 cytokines. It has been shown10 that Th2 cytokines can antagonize the Th1 response. Ideally, 
controlling which cytokines are released would prove beneficial to those suffering from infectious or 
autoimmune diseases. Interest surrounding the medicinal properties of the glycolipid led researchers to 
investigate methods to manipulate the molecule resulting in the controlled release of Th1 and Th2 
cytokines. In the next section previous research involving key KRN7000 derivatives that lead to a biased 
cytokine response will be discussed, including background information leading to the target structures of 
this thesis. 
 
III. Research On KRN7000 Analogs 
A. OCH – A Th2 Biasing Glycolipid 
 Among the analogs of KRN7000 is OCH (Figure 3), a compound which showed bias in the 
release of Th2 cytokines, IL-4 and IL-10. Further studies showed that OCH inhibited experimental 
autoimmune encephalitis12 and collagen-induced arthritis13. Inspired by the ameliorative implications, 
Miyake and coworkers researched the glycolipid’s (Figure 3) effect on type 1 diabetes. Tests were 
conducted on non-obese diabetic mice (NOD), a model for type I diabetes in humans. KRN7000 was used 
as a control to test the activity of OCH.  
 
Figure 3: Structure of OCH  
While observing the incidence of diabetes in 30 week old NOD mice that were given multiple doses of 
OCH at 5 weeks of age, the glycolipid showed comparable inhibition results (reduction from 75% to 
27%) to KRN7000. In an experiment observing insulitis (inflammation of islets of the pancreas, which 
can lead to diabetes), the inflammations were categorized by the amount of inflamed areas observed 
(Figure 4). 
To observe levels of insulitis pancreatic sections were removed and examined. Data showed 
lower grade 3 levels and higher grade 0 levels in mice dosed with OCH compared to mice dosed with 
KRN7000. Although OCH was not as potent in the stimulation of NKT cells (as KRN7000), the 
glycolipid showed more inhibitory effect of insulitis in the microscopic appearance of pancreatic samples. 
Overall, OCH has provided evidence indicating its inhibition of insulitis and diabetes.14 
 
 Figure 4: Levels of insulitis inflammation 
  OCH test results have been debated14 between researchers trying to determine plausible reasons 
for its superiority over KRN7000 in models for diabetes. Variables, such as defects in NKT cells,14 might 
have led to an increase of NKT cells in transgenic mice, which would give off more Th2 cytokines, 
contaminating the accuracy of the results for cytokine release. The results for the spontaneous 
development of diabetes could have been shifted in favor of the OCH glycolipid if there were any 
bacterial infections in the mice, because a combination of mycobacterium extract with KRN7000 would 
cause the NKT cells to predominately produce Th1 cytokines,15 nullifying the Th2 effect. Although these 
are not definitively the reasons behind the results, the fact remains that OCH has shown a biased release 
of Th2 cytokines, IL-4 and IL-10, and has assisted validation of the pursuit of altering the glycolipid 
structure to provide controlled responses. Another area of interest concerning the alteration of the 
glycolipid structure and controlled cytokine release is the glycosidic bond between sugar and ceramide. 
Discussion below will focus more on research concerning the glycosidic bond between sugar and 
ceramide. 
 
 B. Anomeric Replacement: α-C-GalCer 
 It is known that KRN7000 releases high levels of both Th1 and Th2 cytokines (i.e. IFN-γ and IL-
4, respectively, are generally monitored). Moreover, the unbiased release antagonizes the health benefits 
related to both types of cytokines. Research16 on encephalomyelitis in mice has shown that a synthetic 
analogue possessing a truncated sphingosine chain resulted in stimulating of the release of only IL-4, 
which better protected mice from encephalomyelitis. This alteration to the glycoside led researchers16-17 to 
synthesize a KRN7000 derivative with a hydrophobic methylene (CH2) as the glycosidic link between the 
sugar and ceramide instead of the hydrophilic oxygen (O) (Figure 5). The substitution was meant to deter 
α-galatosidase catabolism in vivo18-19 and allow observation of any difference in NKT cell stimulation. 
a-C-GalCer
H2C
NH
OH
O
HO
HO
HO
OH
O C25H51
OH
C14H29
 
Figure 5: Franck and Tsuji’s methylene galactosylceramide17 
 In multiple comparisons between KRN7000 and α-C-GalCer, test results consistently provided 
data17,20-21 which led to the conclusion that α-C-GalCer is a better candidate for the treatment of infectious 
and autoimmune diseases than KRN7000. Comparison tests17 regarding malaria have shown that α-C-
GalCer’s antimalaria effect lasted 3 days longer than KRN7000. In regards to tumor studies20 α-C-GalCer 
has been shown to exhibit similar T cell stimulation to KRN7000 when using a dosage 1000 times less 
than KRN7000. A binding stability experiment20 showed that α-C-GalCer required less time to bind to 
NKT cells and stimulated the cells more significantly than KRN7000. In more recent studies,21 α-C-
GalCer was used as an adjuvant to a live attenuated influenza virus vaccine and was shown to increase the 
immunogenicity and enhance protection provided by the vaccine in wild type mice. The next section will 
discuss previous research conducted in the Howell group focusing particularly on the glycosidic bond. 
 C. α-S-GalCer  
 The emerging understanding and medicinal potential of the α-glycosylceramides had 
attracted the attention of the Howell group.10 Previous research in our group related to glycolipids was 
inspired by the KRN7000 derivative α-C-GalCer. The comparison of the CH2 glycolipid to KRN7000 has 
previously been discussed and has led to the conclusion that alterations to the glycosidic bond can have 
biased and beneficial effects. Following that approach an investigation22 was conducted exploring the link 
between the sugar and ceramide. One previous glycolipid target in the group was α-S-GalCer 3.  
This approach took advantage of treating a nucleophilic ceramide with an electrophilic sugar 
donor. Ceramide 1 (Scheme 1) was treated with phosphorus pentasulfide forming 2. Glycosylation was 
attempted using a trichloroacetimidate activated by a Lewis acid but unfortunately no desired product 3 
was isolated. Thiol glycosylation following the above method had been previously reported 
successfully23, but researchers used simple alkyl acceptor groups in comparison to the ceramide.  
   
Scheme 1: Glycosylation of a protected α-S-GalCer 
Another approach was attempted, targeting α-S-GalCer (Scheme 2). Beginning with phytosphingosine 4, 
the molecule was Boc-protected, fully silyl protected, selectively deprotected, and then brominated 
following Yamamoto’s procedure forming the electrophilic alkyl chain, 5. Following precedent 
literature22 α-S-GalCer 7 was synthesized as an inseparable anomeric mixture. The thiol sugar was then 
alkylated using Schimdt’s reported approach, resulting in the protected glycolipid 6. The thiol glycoside 
was fully deprotected and acylated to form the targeted α-S-GalCer 7.  
 
Scheme 2: Synthesis of α-S-GalCer 
The successfully synthesized α-S-GalCer was tested for biological activity,22 and although it 
shared a similar structure to KRN7000, it did not show any biological activity. One speculation was that 
oxidation of the thiol glycoside could have occurred, interfering with interaction between the S-GalCer 
and NKT cell. Although the S-GalCer may not have shown beneficial effects in regards to NKT cell 
stimulation, it provided information regarding substitution of oxygen with a closely related atom. 
Continuation of the glycosidic link investigation by the Howell group led to the goals of this thesis. 
 
IV. Target Of Research (α-N-GalCer) 
The goals of this thesis were to synthesize α-N-GalCer 8 and α-N-formyl-N-GalCer 9 (Figure 6). 
These targets were chosen because we were inspired by α-C-GalCer’s bioactivity and wanted to 
synthesize glycosylceramides that carried similarities but had not been explored previously. The next two 
sections will discuss literature methods used to approach N-glycosides. 
 Figure 6: Target α-N-GalCer molecules 
 
A. Approach To α-N-GalCer’s 
 As with S-GalCer’s there are two main approaches to synthesizing N-glycosides. The first 
couples an electrophilic sugar donor with an amine. The next method utilizes a nucleophilic sugar coupled 
with an electrophile.   
Some researchers have reported creating alkylglycosylamines by coupling simple aminoalkyl 
groups with unprotected sugar donors (Scheme 3).24-25  In relation to the sugar, mannose commonly 
results in alpha glycosylations, while glucose and galactose yield alpha and beta glycosylated products 
(beta predominating).26  There have been no reports of the synthesis of N-glycosylceramides. Marisa 
Blauvelt, in the Howell group did try to glycosylate an aminoceramide using an unprotected sugar donor, 
but the approach was unsuccessful. 
 
Scheme 3: Formation of an alkylglycosylamine using mannose.  
 An alternative approach would be to use a halide donor sugar. Our group has experience coupling 
galactosyl iodides or bromides with ceramides or related sphingoid bases. Consequently we will examine 
the reaction of these glycosyl halides with aminoceramides. Glycosylations reported by Jacquelyn 
Gervay-Hague26 treated an alpha sugar donor with a sphinganine (acceptor) resulting in an alpha 
glycosylated product. To synthesize the first target (8) a similar approach to Jacquelyn Gervay-Hague’s 
will be attempted (Figure 7). 
 
Figure 7: Approach to α-N-GalCer 
 Regarding the second approach to forming α-N-GalCer’s (mentioned above) there have been 
reports25 of successfully synthesizing α-N-GalCer’s using nucleophilic sugar donors (Scheme 4). For 
example, the synthesis of spicamycin27 involves a nucleophilic sugar donor reacting with an electrophilic 
chloropurine. The sugar 10 underwent azide formation using trimethylsilyl azide. Azide 11 was reduced 
using hydrogen with Lindlar’s catalyst, forming 12. The heterocylic alkylation via amide coupling formed 
13.  
Scheme 4: Formation of alkylglycosylamine using galactose. 
 
B. Approach To α-N-formyl-N-GalCer 
A proposed method to the synthesis of α-N-formyl glycolipids was found in recent chemistry28 
performed by Danishefsky’s group. Their investigation of complex chemistry was inspired by the 
Passerini reaction29 (Figure 8). The reaction (also referred to as an acyl transfer) called for a carboxylic 
acid and an isonitrile resulting in an amide product. 
  
Figure 8: Passerini Reaction. 
 
Danishefsky proposed a mechanism between the isonitrile and carboxylic acid (Figure 9), as illustrated in 
a reported reaction using a fully protected isonitrile and aspartic acid (Scheme 5). This reactions outcome 
has been shown to be influenced anomerically by the isonitrile used for the acyl transfer; an alpha 
isonitrile would result in an alpha formylated product and a beta isonitrile would result in a beta 
formylated product.  
 
Figure 9: Danishefsky’s proposed acyl  transformation. 
 
Scheme 5: Acyl transfer using tetrabenzylated isonitrile and aspartic acid. 
 Our initial approach to α-N-formyl-N-GalCer 9 will take advantage of Danishefsky’s method 
(discussed above) to form N-formyl glycolipids. An alpha nucleophilic sugar donor will be treated with an 
electrophilic ceramide acceptor (Figure 10) to synthesize our desired formyl product.  
 
 Figure 10: Approach to α-N-formyl-N-GalCer 
V. Summary 
 Past research has shown that KRN7000 anomeric replacements (e.g. α-C-GalCer) have produced 
interesting results. Further investigations on these replacements would lead to a better understanding of 
the glycolipid structure and potentially biased T cell stimulation. The Howell group’s research has 
reported that it is possible to synthesize α-S-galactosylceramides. The investigations in this thesis have 
been focused on anomeric replacement with nitrogen.  
 
Results and Discussion 
 I. Research Objective 
  The goals of these studies were: 
  1. To synthesize an α-N-galactosylceramide analog of KRN7000 
  2. To synthesize an α-N-formyl-N-galactosylceramide analog of KRN7000 
3. To compare NKT cell stimulatory abilities of α-N-galactosylceramide and α-N-formyl- 
N-galactosylceramide to their parent compound KRN7000 in collaboration with the lab  
of Professor Brian Wilson of the University of Florida 
 
 II. Synthesis Of α-N-galactosylceramide 
A simple and straightforward method was required for the synthesis of the complex structure of 
α-N-galactosylceramide. Since the Howell group had success with coupling galactosyl halides with 
ceramides or related sphingoid bases this method was examined first.  As mentioned before (Figure 7, pg. 
10), the glycolipid will be broken down into two groups an aminoceramide and a halosugar. The ceramide 
will be synthesized by coupling a fatty acid chain with phytosphingosine. 
Following Sanghee’s reported30 α-GalCer approach (Scheme 6), the synthesis of α-N-GalCer 
began by coupling commercially available cerotic acid with N-hydroxysuccinimide, providing ester 14a 
in 43% yield.  Due to the esters less than moderate yields an alternate ester formation was examined.31 
Cerotic acid was treated with p-nitrophenol to afford ester 14b in 60% yield. Ester 14b could be isolated 
using column chromatography, but it was also found that purification of 14b could be accomplished by 
recrystallization using ethyl acetate giving 75% yield. The ester was then coupled to phytosphingosine, 
forming ceramide 15, isolated in 99% yield. Previously this had been purified via column 
chromatography, but it was discovered that 15 could also be purified by recrystallization using ethyl 
acetate. Ceramide 15 was then fully silyl protected, providing 16 in 93% yield. Selective deprotection 
gave the free primary alcohol 17 in 62% yield. The original procedure30 called for 10% trifluoroacetic 
acid (TFA), but the reaction did not reach completion until the concentration of TFA was increased to 
50%. An amination similar to the Gabriel synthesis32 was then performed on alcohol 17. The selectively 
deprotected ceramide was treated with phthalimide under Mitsunobu conditions, forming 18 in 76% yield. 
Selective deprotection of 18 using hydrazine was attempted. Although the starting material was 
consumed, based on TLC, we were unable to isolate clean aminoceramide 19. As proof of aminoceramide 
formation, it was acetylated. Although pure acetylated product was not isolated, 13C NMR data from the 
acetylation showed two carbonyl peaks, which led us to believe that aminoceramide 19 was successfully 
synthesized. The glycosylation of 19 was attempted but no desired product was isolated. Consequently, 
the approach was revised.  
 Scheme 6: Attempted synthesis of aminoceramide 
 
 The Howell group has found that working with sphinganines (aminodiols) rather than 
phytosphingosines (aminotriols), is sometimes more straightforward. We decided to proceed with the 
synthesis using a protected sphinganine (Figure 11). Prior to the ceramide formation the aminodiol will be 
coupled with the halosugar donor. The sphingoid base will be formed using a simple and selective route.33  
O
HO OH
HO
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Figure 11: Approach to revised α-N-GalCer 
Following a procedure developed in the group33 (Scheme 7) the synthesis of the selectively 
protected sphingoid base began by treating Boc-protected serine with methoxy(methyl)amine 
hydrochloride, forming Weinreb amide 20. This was treated with two equivalents of a sacrificial base to 
deprotonate the primary alcohol of the carbonate. Then, pentadecylmagnesium bromide was added, 
forming ketone 21 in 62% yield over two steps. The alcohol was silyl protected, providing 22 in 85% 
yield. The protected sphinganine was then reduced, giving the secondary alcohol 23 in 50% yield. 
Benzylation gave the fully protected sphingoid base 24 in 54% yield. Selective deprotection provided 25 
in 25% yield. The low yield in the deprotection was due to loss of material during work-up. The primary 
amine was formed following the same procedure described in the attempted synthesis of the 
aminoceramide 19. Reaction with phthalimide gave 26 in 61% yield. A deprotection was attempted using 
sodium borohydride with acetic acid in isopropyl alcohol,34 but no desired product was isolated. An 
alternate deprotection with hydrazine produced 27 in 25% yield. During purification of the phthalimide 
deprotection via TLC plate a second spot was observed close to the desired product. This had also been 
observed with the attempted aminoceramide purification. The 1H and 13C NMRs showed only the desired 
aminodiol in the isolated product.  
 
Scheme 7: Synthesis of sphingoid base 
 
The synthesis of the glycosyl donor began with commercially available methyl-α-D-
galactopyranoside(28) (Scheme 8). Following the approach of Jacquelyn Gervay-Hague’s reported 
halosugar synthesis,35 global benzyl protection of methoxygalactoside, followed by anomeric hydrolysis 
gave 29 in 9% yield over two steps. Acetalyation of the lactol formed 30. Purification of 30 did not afford 
a sufficient yield so the product was obtained by a labmate. Treatment of the acetylated sugar with 
hydrobromic acid provided bromosugar 31. Due to its sensitivity to silica gel, the sugar was directly used 
in the glycosylation without purification. 
 Scheme 8: Synthesis of bromosugar 
 
 Glycosylation of the protected aminosphingoid base 27 with bromosugar 31 was performed 
following a method reported by Jacquelyn Gervay-Hague (Scheme 9).26 A compound that displayed 
similar spectral characteristics to the desired product was observed but, unfortunately, could not be 
isolated.  
 
Scheme 9: Attempted synthesis of revised α-N-GalCer 
 
III. Synthesis Of α-N-formyl-N-galactosylceramide 
Our synthesis of α-N-formyl-N-galactosylceramide (9) will require treatment of an electrophilic 
sugar with a nucleophilic ceramide (Figure 12). Based on the study reported by Danishefsky28 (Scheme 5, 
pg. 12) we will treat an isonitrile with a carboxylic acid derived from  the corresponding ceramide. The 
beta isonitrile will be used to test the methodology of the acyl transfer reaction. Once the methodology 
proves successful, the alpha isonitrile will be used to create the desired N-formyl glycolipid. The isonitrile 
will be synthesized using Danishefsky’s methods, and the acid will be synthesized by oxidation of the 
ceramide’s primary alcohol. 
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Figure 12: Approach to α-N-formyl-N-GalCer 
 
A model study was conducted prior to the α-N-formyl-N-GalCer synthesis, to test Danishefsky’s 
reported acyl transfer (Scheme 5, pg. 12).28 Commercially available aspartic acid 34 was treated with 
isonitrile 33, prepared by labmate Dr. Stewart Richardson, giving 35 in 52% yield (Scheme 10). The 
results of this study gave us enough cause to pursue the acyl transfer with ceramide. 
 
 
Scheme 10: Danishefsky’s reported acyl transfer reaction 
 
   The approach towards 9 began with previously synthesized ceramide alcohol 17 (Scheme 6, pg. 
14). Following a procedure presented by Danishefsky,28 compound 17 was oxidized to carboxylic acid 36 
in 37% yield (Scheme 11).  Excess TEMPO and BAIB were necessary to complete the conversion to 
carboxylic acid. The acid was then treated with the protected isonitrile 33 to form product 37. 
Unfortunately, the desired product from the acyl transfer reaction was not observed.  
 
 Scheme 11: Attempted synthesis of α-N-formyl-N-GalCer 
 
Messy TLC and NMR data led to concerns about the stability of the ceramide under the high 
temperature reaction conditions. Byproducts observed via TLC showed potential signs of ceramide 
decomposition (e. g. deprotections). An alternate approach will be taken to address steric complications 
with the ceramide and take advantage of our previously synthesized sphingoid base 25.  
 The reaction conditions for the acyl transfer reaction reported by Danishefsky appeared to be too 
harsh for the ceramide-derived carboxylic acid. It was decided that a simpler structure and different 
protecting groups may tolerate the reaction conditions better. The alternative route will use the protected 
isonitrile 33 and an oxidized form of the sphingoid base (creating the acid) for the acyl transfer (Figure 
13). As stated previously, a beta isonitrile will be used to test the methodology of the acyl transfer with 
the sphingoid base. 
 
 
Figure 13: Revised approach to α-N-formyl-N-GalCer 
Sphingoid base 25 (Scheme 7, pg. 16) was oxidized to carboxylic acid 37 in 81% yield (Scheme 12). Acid 
38 was reacted with 32 to form the revised α-N-formyl-N-GalCer product 39. Unfortunately no desired 
product was isolated, and NMR data showed evidence of byproducts. It was concluded that high 
temperatures caused the decomposition of the protected sphingoid base and ceramide which led to the 
unsuccessful acyl transfer with the protected isonitrile.  
 
 
Scheme 12: Attempted synthesis of revised α-N-formyl-N-GalCer 
 
Conclusion 
 The syntheses of complex amino glycosides have been shown to hold a few obstacles. The 
synthesis of the aminoceramide was not completed due to complications during purification. The 
acetylation of an isolated aminotriol did suggest that the aminoceramide was synthesized, but in the next 
reaction no glycosylated product was isolated. The alternative α-N-GalCer glycosylation using a 
sphingoid base, resulted in a compound with similar spectral characteristics to the desired product, but the 
glycosylated sphinganine was not isolated.  The α-N-formyl-N-GalCer synthesis was also not successful. 
Based on 1H NMR and TLC, it appeared that decomposition of the ceramide and sphinganine carboxylic 
acids occurred under the reaction conditions.  
 Future attempts to synthesize amino galactosylceramides will continue to focus on using 
aminosphingoid base derivative 35. The α-N-formyl-N-GalCer approach will focus on identifying less 
extreme conditions. One approach would use a fully deprotected isonitrile 40 (Figure 14). The formation 
of the N-formyl group is driven by hydrogen bonding of the free C2’’ hydroxyl group on the sugar 
providing compound 41,36 followed by deprotection of the silyl groups to obtain target 9. 
 
Figure 14: Formation of N-formyl-N-GalCer using unprotected isonitrile 
 
 Another approach uses an acylated thiolphenol as opposed to a carboxylic acid in the acyl 
transfer reaction.36 The product will be a di-thiophenol substituted carbon 43 (Scheme 13), but this can be 
hydrolyzed to the formyl group using p-toluenesulfonic acid in water to afford the α-N-formyl-N-
galactosylceramide product 44, followed by full deprotection to provide desired target 9. 
 
 
Scheme 13: Formation of N-formyl-N-GalCer using thiophenol  
 
Experimental 
General. Melting points were determined in open Pyrex capillary tubes and are uncorrected. Infrared 
spectra were recorded on a Nicolet 750 FT-IR spectrometer. 1H NMR spectra were recorded at 300 MHz 
on a Bruker Avance Ultrashield 300-NMR spectrometer, at 400 MHz on a Bruker Avance DRX-400 
NMR spectrometer, and at 500 MHz on a Bruker Avance 500-NMR spectrometer. Chemical shifts (δ) are 
reported in ppm and coupling constants (J) are reported in Hertz. Abbreviations used are as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = doublet of doublets, ddd = 
doublet of double of doublts, dt = doublet of triplets. 13C NMR spectra were recorded on a Bruker Avance 
Ultrashield 300-NMR spectrometer at 75 MHz, on a Bruker Avance DRX-400 NMR spectrometer at 100 
MHz, or on a Bruker Avance 500-NMR spectrometer at 125 MHz. High-resolution mass spectra were 
determined by the Mass Spectroscopy Facility in the Department of Chemistry at the University of 
Connecticut in Storrs, Connecticut and the Mass Spectroscopy Facility in the Department of Chemistry 
and Biochemistry at the University of Notre Dame in Notre Dame, Indiana. Column chromatography was 
performed with flash silica, 40 microns. Thin-layer chromatography was carried out on silica gel (Silica 
Gel 60 F254) glass plates. Spots were visualized by UV and/or 10% molybdic acid in ethanol.  
Tetrahydrofuran was obtained from a distillation dispensing unit under neutral alumina (CH2Cl2, pyridine, 
and toluene were obtained in the Chemistry Department stock room located at University of Connecticut 
in Storrs, Connecticut and dried over 4Ǻ MS). 
 
Hexacosanoic acid 2,5-Dioxo-pyrrolidin-1-yl ester (14a) 
Hexacosanoic acid (0.50 g, 1.3 mmol) was dissolved in CH2Cl2 (15 mL) under N2 at rt. EDC (0.27 g, 1.4 
mmol) and N-hydroxysuccinimide (0.18 g, 1.6 mmol) were added to the solution. The reaction mixture 
was heated to 40 °C for 6 h. The reaction was diluted with H2O (10 mL), and the organic layer was 
extracted with Et2O (30 mL). The organic layer was then washed with brine (10 mL), dried (MgSO4), and 
concentrated under reduced pressure. Purification by flash chromatography on silica gel (PetEt/EtOAc 
85:15) afforded 14a as a white solid (0.28 g, 43%):33 1H NMR (300 MHz, CDCl3) δ 2.83 (s, 4H), 2.59 (t, 
J = 7.5 Hz, 2H), 1.74 (m, 2H), 1.39 (m, 2H), 1.25 (m, 42H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (75 MHz, 
CDCl3) δ 169.1, 168.6, 31.9, 30.9, 29.7, 29.6, 29.5, 29.3, 29.1, 28.8, 25.6, 24.5, 22.7, 14.1 
O C25H51
O
O2N
 
p-Nitrophenyl hexacosanoate (14b) 
Hexacosanoic acid (1.0 g, 2.5 mmol) was dissolved in CH2Cl2 (260 mL) under N2 at rt. p-Nitrophenol 
(0.39 g, 2.8 mmol), DMAP (0.060 g, 0.51 mmol), and DCC (0.55 g, 2.7 mmol) were added to the reaction 
flask, and the mixture was stirred for 8 h. The solution was filtered, and the filtrate was concentrated 
under reduced pressure. Purification by recrystallization (EtOAc) afforded 14b as a yellow solid (0.98 g, 
75%):31 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.1 Hz, 2H), 7.30 (d, J = 9.3 Hz, 2H), 2.62 (t, J = 7.5 
Hz, 2H), 1.78 (m, 2H), 1.28 (m, 44H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.3, 
155.5, 145.2, 125.2, 122.4, 34.3, 31.9, 29.7, 29.7, 29.6, 29.6, 29.4, 29.4, 29.4, 29.2, 29.0, 24.7, 22.7, 14.1. 
 
Hexacosanoic acid (2,3-Dihyroxy-1-hydroxymethylheptadecyl) amide (15) 
p-Nitrophenyl hexacosanoate (14b) (0.46 g, 0.89 mmol) was dissolved in pyridine (17 mL) under N2 at rt. 
Phytosphingosine (0.23 g, 0.74 mmol) was then added, and the solution was allowed to stir for 65 h. The 
solution was then concentrated under reduced pressure. Purification by recrystallization (EtOAc) afforded 
15 as a yellow solid (0.51 g, 99%):30 1H NMR (500 MHz, pyr) δ 8.34 (d, J = 8.5 Hz, 1H), 5.10-5.05 (m, 
1H), 4.49 (m, 1H), 4.45 (m, 1H), 4.33 (m, 1H), 4.23 (m, 1H), 2.46 (t, J = 7.3 Hz, 2H), 2.18-1.21 (m, 
72H), 0.88 (t, J = 6.7 Hz, 6H).  
 
(2S,3S,4R)-1,3,4-Tri-t-butyldimethylsilyloxy-2-hexacosanoylaminooctadecane (16) 
Hexacosanoic acid (2,3-dihyroxy-1-hydroxymethylheptadecyl) amide (15) (1.5 g, 2.2 mmol) was 
dissolved in CH2Cl2 (50 mL) at 0 °C. TBSOTf (4.4 g, 17 mmol) and 2,6-lutidine (3.5 g, 33 mmol) were 
added, and the solution was stirred at rt for 10 h. The reaction was quenched with MeOH (12 mL). The 
mixture was then diluted with Et2O (100 mL) and washed with H2O (55 mL), saturated aqueous NaHCO3 
(55 mL), and brine (55 mL). The organic layer was dried (MgSO4), filtered, and concentrated under 
reduced pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 98:2) 
afforded 16 as a colorless oil (2.13 g, 93%):30 1H NMR (300 MHz, CDCl3) δ 5.82 (d, J = 8.7 Hz, 1H) 3.94 
(m, 1H), 3.87 (dd, J = 9.9, 4.2 Hz, 1H), 3.82 (dd, J = 7.2, 1.2 Hz, 1H), 3.67 (m, 1H), 3.63 (dd, J = 9.9, 4.5 
Hz, 1H), 2.14 (t, J = 7.7 Hz, 2H), 1.64-1.46 (m, 6H), 1.25 (m, 66H), 0.93-0.86 (m, 33H), 0.13-0.04 (m, 
18H); 13C NMR (75 MHz, CDCl3) δ 172.2, 75.4, 75.4, 61.4, 52.5, 37.2, 32.2, 31.9, 30.0, 29.7, 29.5, 29.4, 
29.4, 29.4, 26.4, 26.1, 26.1, 25.9, 25.8, 22.7, 18.4, 18.2, 18.2, 14.1, -3.5, -3.8, -4.6, -5.2, -5.2,   -5.6.  
 
(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-1-octadecanol (17) 
(2S,3S,4R)-1,3,4-Tri-t-butyldimethylsilyloxy-2-hexacosanoylaminooctadecane (16) (2.1 g, 2.1 mmol) was 
dissolved in dry THF (31 mL) and cooled to -10 °C. TFA (50% in H2O, 0.84 mL, 11 mmol) was slowly 
added. The reaction was gradually warmed to 10 °C over 5 h. The solution was quenched with saturated 
aqueous NaOH (22 mL) and diluted with Et2O (64 mL). The two layers were separated, and the organic 
layer was washed with H2O (31 mL), saturated aqueous NaHCO3 (31 mL), and brine (31 mL), dried 
(MgSO4), and concentrated under reduced pressure. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc 80:20) afforded 17 as a colorless oil (1.18 g, 62%):30 1H NMR (300 MHz, 
CDCl3) δ 6.24 (d, J = 7.8 Hz, 1H), 4.21 (m, 1H), 4.06 (m, 1H) 3.90 (m, 1H), 3.76 (m, 1H), 3.59 (m, 1H), 
3.15 (m, 1H) 2.18 (t, J = 7.5 Hz, 2H), 1.48-1.62 (m, 6H), 1.25 (m, 66H), 0.93 (s, 9H), 0.91 (s, 9H), 0.85-
0.94 (m, 6H), 0.11 (s, 6H), 0.08 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 172.6, 77.5, 76.4, 63.6, 51.3, 37.0, 
34.4, 31.9, 29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 26.0, 26.0, 25.8, 25.6, 22.7, 18.2, 16.9, 14.1, -3.8, -4.1, -4.5, 
-4.9. 
 
(2S,3S,4R)-2-(N-Pentacosanoylamino)-3,4-di-t-butyldimethylsilanyloxy-1-octadecaphthalimide (18) 
(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-1-octadecanol (17) (0.16 g, 0.18 
mmol) was dissolved in dry THF (26 mL) under N2 at rt. Triphenylphosphine (0.23 g, 0.88 mmol), DIAD 
(0.039 g, 0.19 mmol), and phthalimide (0.031 g, 0.21 mmol) were added, and the solution was stirred for 
3.5 h. The mixture was concentrated under reduced pressure. Purification by flash chromatography on 
silica gel (petroleum ether/EtOAc 95:5) afforded 18 as a clear oil (0.14 g, 76%): [α]25D -5.19 (c 1.4, 
CHCl3); IR (KBr) 2924, 2854, 1717, 1683 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 2.4, 5.4 Hz, 
2H), 7.72 (dd, J = 2.4, 5.4 Hz, 2H) , 5.98 (d, J = 8.1 Hz, 1H), 4.42 (m, 2H), 3.81 (m, 3H), 2.12 (ddd, J  = 
7.6, 7.6, 7.6 Hz,  1H), 2.01 (ddd, J  = 7.6, 7.6, 7.6 Hz, 1H), 1.70 (m, 4H), 1.60 (m, 4H), 1.41 (m, 4H), 1.28 
(br, s, 60H), 1.02 (s, 9H), 0.95 (s, 9H), 0.90 (m, 6H), 0.13 (m, 12H) 13C NMR (100 MHz, CDCl3) δ 172.8, 
169.1, 134.2, 132.2, 123.4, 51.1, 37.8, 37.1, 34.6, 32.1, 30.0, 29.9, 29.9, 29.8, 29.8, 29.6, 29.5, 29.4, 26.3, 
26.3, 26.1, 25.6, 22.9, 18.6, 18.4, 14.3, -3.3, -3.8, -4.3, -4.7; HRMS (TOF) calcd for C64H121N2O5Si2 (M+ 
+ H) 1053.8814. Found  1053.8859.  
 
[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]carbamic acid tert-butyl ester (20) 
Boc-L-serine (6.00 g, 29 mmol) was dissolved in dry CH2Cl2 (115 mL) and the solution cooled to -15 °C 
under N2. N,O-Dimethylhyroxylamine hydrochloride (3.0 g, 30 mmol) was added, followed by N-
methylmorpholine (3.1 g, 30 mmol). After 5 min 1-(3-methylaminopropyl-3-ethylcarbodoiimide 
hydrochloride (5.8 g, 30 mmol) was added in five portions over 30 min. After being stirred for 1 h at   -15 
°C, the reaction was quenched with HCl (1 M, 17 mL), and the layers were separated. The aqueous layer 
was extracted with CH2Cl2 (3 x 34 mL). The organic extracts were combined, washed with saturated 
NaHCO3 (17 mL) and H2O (17 mL), dried (MgSO4), and concentrated to provide 20 as a white solid (5.55 
g, carried to the next step without purification):33 1H NMR (400MHz, CDCl3) δ 5.71 (br, s, 1H), 4.95 (br, 
s, 1H), 3.82-3.78 (m, 5H), 3.23 (s, 3H), 2.90 (br s, 1H), 1.43 (s, 9H). 
 
(2S)-2-(N-tert-Butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (21) 
[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]carbamic acid tert-butyl ester (20) (15 g, 59 mmol) was 
dissolved in dry THF (117 mL) under N2. The solution was cooled to -15 °C, and isopropylmagnesium 
chloride (60 mL, 2 M) was added dropwise, affording a clear solution. After 5 min, pentadecylmagnesium 
bromide (0.26 M in THF, 212 mL, 76 mmol) was added at -15 °C. The resulting solution was allowed to 
warm to rt overnight. The mixture was cooled to -15 °C, and HCl (1 M, 180 mL) was added, followed by 
EtOAc (135 mL). The two layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x 
30 mL). The organic extracts were combined, washed with H2O (270 mL), dried (MgSO4), and 
concentrated. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 85:15) afforded 
21 as a white solid (14 g, 62% over two steps):33 1H NMR (400 MHz, CDCl3) δ 5.48 (br s, 1H), 4.26 (m, 
1H), 3.94 (m, 2H), 2.63 (br s, 1H), 2.55 (m, 2H), 1.57 (m, 2H), 1.45 (s, 9H), 1.27-1.22 (m, 24H), 0.88 (t, J 
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 208.1, 164.0, 80.3, 70.1, 68.9, 63.3, 61.6, 52.3, 49.8, 39.9, 
31.9, 29.7, 29.6, 29.4, 29.3, 29.2, 28.3, 23.5, 22.7, 14.1. 
 
(2S)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-one (22) 
A catalytic amount of DMAP was added to a stirred solution under N2 of (2S)-2-(N-tert-
butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (21) (7.4 g, 19 mmol) and imidazole (3.8 g, 56 mmol) 
in dry DMF (21 mL). After 20 min TBDPSCl (6.1 g, 22 mmol) was added dropwise, and the reaction 
mixture was stirred overnight. In the morning the reaction was diluted with saturated aqueous NH4Cl (50 
mL), and the aqueous layer was extracted with CH2Cl2 (37 mL). The organic layer was washed with H2O 
(37 mL) and brine (37 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on 
silica gel (petroleum ether/EtOAc 98:2) afforded 22 as a clear oil (10 g, 85%):33 1H NMR (400 MHz, 
CDCl3) δ 7.60 (m, 4H), 7.39 (m, 6H), 5.53 (d, J = 7.7 Hz, 1H), 4.33 (m, 1H), 4.04 (dd, J = 10.6, 3.1 Hz, 
1H), 3.90 (dd, J = 10.9, 3.8 Hz, 1H), 2.51 (m, 2H), 1.58 (m, 2H), 1.44 (s, 9H), 1.26 (m, 24H), 1.03 (s, 
9H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 207.4, 155.3, 135.5, 132.8, 129.9, 129.9, 
127.8, 79.8, 64.2, 61.3, 60.3, 41.3, 40.0, 32.1, 29.7, 29.6, 29.6, 29.4, 29.4, 29.3, 29.2, 29.0, 28.3, 27.6, 
26.7, 26.2, 23.3, 22.7, 22.6, 20.9, 20.4, 19.4, 19.2, 18.7, 14.3. 
 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-ol (23) 
LiAl(O-t-Bu)3H (1.1 g, 4.3 mmol) was added to dry EtOH (7.6 mL) at -78 °C under N2. (2S,3R)-2-(N-
tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-one (22) (0.46 g, 0.72 mmol) in 
dry EtOH (7.6 mL) was added to the reaction flask dropwise. After stirring for 6 h at -78 °C the reaction 
mixture was diluted with CH2Cl2 (2.2 mL) and neutralized with 10% citric acid (22 mL). The solution 
was allowed to stir and reach rt over 1.5 h. The cloudy suspension was extracted with CH2Cl2 (3 x 7 mL). 
The organic extracts were combined and washed with H2O (4 x 7 mL). The organic layer was then 
washed with brine (7 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on 
silica gel (petroleum ether/EtOAc 95:5) afforded 23 as a clear oil (0.23 g, 50%):33 1H NMR (300 MHz, 
CDCl3) δ 7.62 (m, 4H), 7.41 (m, 6H), 5.30 (d, J = 8.1 Hz, 1H), 3.93 (m, 1H), 3.90 (m, 1H), 3.67 (m, 1H), 
3.57 (br s, 1H), 2.88 (m, 2H), 1.44-1.06 (m, 45H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 
155.9, 135.8, 132.8, 132.7, 130.2, 130.1, 128.1, 128.0, 79.6, 74.0, 64.4, 54.7, 34.7, 32.1, 31.1, 29.8, 29.6, 
28.6, 27.1, 26.1, 22.9, 19.4, 14.3. 
 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxy-3-benzyloxyoctadecane (24) 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-ol (23) (0.14 g, 0.21 
mmol) was dissolved in dry DMF (1 mL) under N2 and cooled to 0 °C. Tetrabutylammonium iodide (0.12 
g, 0.32 mmol) and sodium hydride (60% in mineral oil, 0.0070 g, 0.30 mmol) were then added. After 15 
min benzylbromide (0.055 g, 0.32 mmol) was added dropwise via syringe. The solution was allowed to 
stir at 0 °C for an additional 15 min before it was removed from the cooling bath and allowed to stir at rt 
for 45 min. The reaction was then quenched with saturated aqueous NH4Cl (2 mL), and the solution was 
extracted with EtOAc (4 x 3 mL). The combined organic extracts were washed with H2O (3 mL) and 
brine (3 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc 97:3) afforded 24 as a clear oil (0.085 g, 54%):33 1H NMR (300 MHz, CDCl3) δ 
7.65 (m, 4H), 7.63-7.27 (m, 11H), 4.71 (d, J = 8.0 Hz, 1H), 4.54 (d, J = 11.3 Hz, 1H), 4.49 (d, J = 11.3 
Hz, 1H), 3.86 (m, 2H), 3.72 (dd, J = 9.0, 4.1 Hz, 1H), 3.58 (m, 1H), 1.42 (s, 9H), 1.42 (s, 2H), 1.26 (br s, 
26H), 1.05 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 155.8, 138.8, 135.9, 133.5, 
130.0, 128.5, 128.0, 127.7, 79.3, 79.1, 72.3, 63.1, 53.7, 32.2, 30.7, 30.1, 29.9, 29.9, 29.8, 29.6, 28.6, 27.1, 
25.6, 22.9, 19.5, 14.4. 
 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25) 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxy-3-benzyloxyoctadecane (24) 
(0.15 g, 0.20 mmol)  was dissolved in THF (0.8 mL) under N2, and  the solution was cooled to 0 °C. 
TBAF (0.11 mL, 1.0 M in THF) was added, and the solution was stirred for 4 h at rt. The reaction mixture 
was concentrated, and the residue was dissolved in CH2Cl2 (2.4 mL). The solution was washed with brine 
(5 mL), dried (MgSO4) and concentrated again. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc 80:20) afforded 25 as a white solid (0.025 g, 25%):33 1H NMR (400 MHz, 
CDCl3) δ 7.32 (m, 5H), 5.27 (d, J = 7.4 Hz, 1H), 4.63 (d, J = 11.4 Hz, 1H), 4.48 (d, J = 11.4 Hz, 1H), 3.95 
(m, 1H), 3.65 (m, 3H), 2.95 (s, 1H), 1.67 (m, 1H), 1.44 (s, 9H), 1.26 (br s, 27H), 0.88 (t, J = 6.8 Hz, 3H); 
13C NMR (100 MHz, CDCl3) δ 156.2, 138.2, 128.7, 128.1, 128.0, 82.0, 79.6, 73.0, 62.5, 53.5, 32.1, 31.5, 
30.0, 29.9, 29.9, 29.8, 29.7, 29.6, 28.6, 25.8, 22.9, 14.3. 
 
(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecapthalimide (26) 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25) (1.0 g, 2.0 mmol) was 
dissolved in dry THF (160 mL) at rt under N2. Triphenylphosphine (2.7 g, 10 mmol), DIAD (0.45 g, 2.2 
mmol), and phthalimide (0.36 g, 2.4 mmol) were added, and the solution was stirred for 3.5 h. The 
mixture was concentrated under reduced pressure. Purification by flash chromatography on silica gel 
(petroleum ether/EtOAc 90:10) afforded 26 as a white solid (0.77 g, 61%): mp 84-88 °C; [α]25D -27.3 (c 
3.4, CHCl3); IR (KBr) 2924, 2854, 1717 cm-1: 1H NMR (300 MHz, CDCl3) δ 7.75 (br s, 2H), 7.61 (br s, 
2H), 7.24 (m, 5H), 4.87 (d, J = 9.3 Hz, 1H), 4.61 (d, J
 
= 11.7 Hz, 1H), 4.41 (d, J = 11.7 Hz, 1H),  4.06 (br 
s, 1H), 3.75 (m, 2H), 3.51 (br s, 1H), 1.69 (br s, 1H), 1.40 (br s, 3H), 1.20 (s, 23H), 1.11 (s, 9H), 0.81 (t, J 
= 6.3 Hz, 3H) 13C NMR (75 MHz, CDCl3) δ 168.7, 155.9, 138.6, 133.9, 132.4, 128.6, 127.2, 123.3, 80.7, 
79.3, 77.6, 77.2, 76.8, 72.3, 51.8, 38.0, 32.1, 31.2, 30.0, 29.9, 29.9, 29.8, 29.7, 29.5, 28.2, 25.7, 23.1, 22.9, 
14.3; HRMS (TOF) calcd for C38H57N2O5 (M+ + H) 621.4267. Found 621.4289.  
 
(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecamine (27) 
(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecapthalimide (26) (1.5 g, 2.5 mmol) was 
dissolved in MeOH (15 mL) at rt under N2. The solution was treated with hydrazine monohydrate (0.18 g, 
3.7 mmol) and allowed to stir for 3 h at 65 °C. After 2 h a TLC (CH2Cl2/MeOH 98:2) showed starting 
material; so hydrazine (0.060 mL, 1.2 mmol) was added. A white precipitate resulted. After 1 h the 
mixture was passed through Celite and concentrated. Purification by flash chromatography on silica gel 
(CH2Cl2/MeOH 98:2) afforded 27 as a yellow oil (0.29 g,  25%): [α]25D -11.0 (c 1.7, CHCl3); IR (KBr) 
3447, 2924, 2854, 1717 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.21 (m, 5H), 5.01 (d, J = 7.8 Hz, 1H), 4.57 
(d, J
 
= 11.4 Hz, 1H), 4.43 (d, J = 11.4 Hz, 1H), 3.59 (m, 1H), 3.48 (m, 1H), 2.80 (br, s, 2H), 1.55 (m, 2H), 
1.38 (s, 9H), 1.20 (s, 26H), 0.83 (t, J = 6.3 Hz, 3H) 13C NMR (75 MHz, CDCl3) δ 156.2, 138.8, 128.7, 
128.0, 127.9, 81.0, 79.4, 72.5, 54.5, 41.7, 32.1, 31.1, 30.1, 29.9, 29.9, 29.8, 29.7, 29.6, 28.6, 25.8, 22.9, 
14.3; HRMS (TOF) calcd for C30H55N2O3 (M+ + H) 491.4213. Found 491.4196. 
 Methyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranoside (28) 
Sodium hydride (60% in mineral oil, 2.5 g, 103 mmol) in DMF (50 mL) was added to methyl-α-D-
galactopyranoside (28) (2.0 g, 10 mmol) in two fractions. The flask was then placed in a cold water bath 
for 30 min. BnBr (11 g, 62 mmol) in DMF (10 mL) was then added to the reaction flask. The reaction 
was stirred at rt for 12 h under N2 flow. The solution was neutralized with brine (25 mL), and the organic 
layer was extracted with Et2O (50 mL x 3). The combined organic layers were washed with water (50 mL 
x 3) and brine (50 mL), dried (MgSO4), and concentrated under reduced pressure. The product was 
carried to the next step without further purification.35 
 
2,3,4,6-Tetra-O-benzyl-D-galactopyranose (29) 
Methanesulfonic acid (2.1 g, 21 mmol) was dissolved in H2O (10 mL). Methyl 2,3,4,6-tetra-O-benzyl-α-
D-galactopyranoside (28)  (7.9 g, 14 mmol) was dissolved in acetic acid (60 mL). The methanic sulfonic 
acid solution was then added dropwise to the galactopyranoside solution. The  resultant solution was 
heated to 80 °C for 6.5 h. The mixture was then cooled to rt and concentrated under reduced pressure. 
Purification by flash chromatography on silica gel (petroleum ether/EtOAc 7:3) afforded 29 as a colorless 
oil (0.72 g, 9% over two steps):35 1H NMR (200 MHz, CDCl3) δ 7.40-7.18 (m, 20H), 5.97-4.36 (m, 8H), 
5.27 (d, J = 3.6 Hz, 1H), 4.19-3.45 (m, 6H). 
 
 1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-D-galactopyranose (30) 
2,3,4,6-Tetra-O-benzyl-D-galactopyranose (29) (0.72 g, 1.3 mmol) was dissolved in pyridine (3 mL) and 
was cooled to 0 °C. Acetic anhydride (0.27 g, 2.6 mmol) was then added to the reaction flask dropwise. 
The reaction was stirred overnight. The mixture was diluted with EtOAc (3 mL) and washed with ice cold 
water (3 mL). The organic layer was then separated and washed with water (3 mL) and brine (3 mL), 
dried (MgSO4), and concentrated under reduced pressure. 1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-D-
galactopyranose (30) was not purified.35 
 
2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl bromide (31) 
1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-D-galactopyranose (30) (0.20 g, 0.34 mmol) was dissolved in 
CH2Cl2 (9 mL) and cooled to 0 °C. HBr (33% in AcOH) (0.17 mL) was then added to the reaction flask 
dropwise. The solution was allowed to stir for 1.5 h. The reaction mixture was then poured over ice cold 
saturated aqueous NaHCO3 (10 mL) and stirred slowly. The organic and aqueous layers were separated. 
The aqueous layer was extracted with cold EtOAc (10 mL x 3). The combined organic layers were 
washed with water (10 mL) and brine (10 mL), dried (MgSO4), and concentrated under reduced pressure. 
The product (31) was used without further purification.37 
 
 
 Nα-(Fluoren-9-ylmethyloxycarbonyl)-Nγ-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-Nγ-formyl-
L-asparagine-t-butyl-ester (35) 
Aspartic acid (34) (0.027 g, 0.066 mmol) was added to 2,3,4,6-Tetra-O-benzyl-β -D-galactopyranosyl 
isonitrile (33) (0.025 g, 0.046 mmol) in anhydrous CHCl3 under N2. The reaction mixture was sealed and 
heated to 150 °C in a microwave for 45 minutes. Once the reaction was complete the solvent was remove 
via reduced pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 3:1) 
afforded 35 as a yellow oil (0.023 g, 52%):28 1H NMR (400 MHz, CDCl3) δ 9.3-8.5 (br, 1H), 7.68 (d, J = 
7.5 Hz, 2H), 7.53-7.51 (m, 2H), 7.31 (t, J = 7.6 Hz,  2H), 7.26-7.11 (m, 22H), 5.61 (d, J = 9.0 Hz, 1H), 
5.48 (d, J = 9.6 Hz, 1H), 4.90 (d, J = 10.8 Hz, 1H), 4.74 (d, J = 10.3 Hz, 1H), 4.65 (d, J = 11.7 Hz, 2H), 
4.54-4.48 (m, 2H), 4.43-4.30 (m, 5H), 4.23 (t, J = 7.4 Hz, 1H), 4.15 (m, 1H), 3.94 (s, 1H), 3.60-3.59 (m, 
2H), 3.49 (m, 1H), 3.42 (m, 1H), 3.32 (m, 1H), 3.20 (m, 1H), 1.35 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 
169.8, 164.5, 162.1, 156.0, 143.9, 143.8, 141.3, 141.3, 138.5, 137.9, 137.6, 128.5, 128.4, 128.3, 127.9, 
127.8, 127.7, 127.6, 127.5, 127.1, 125.2, 125.1, 119.9, 82.4, 77.6, 75.9, 74.6, 73.6, 73.1, 72.6, 68.0, 67.1, 
50.7, 47.1, 27.8 
 
 (2S,3S,4R)-2-(N-Hexacosanoylamino)-3,4-di-tert-butyldimethylsilanyloxy-1-octadecanoic acid (36) 
(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-4-octadecanol (17) (0.10 g, 0.11 
mmol) was dissolved in CH2Cl2 (4.4 mL)/H2O (2.2 mL) at rt under N2. TEMPO (0.0030 g, 0.022 mmol) 
followed by BAIB (0.087 g, 0.27 mmol), was added to the reaction flask. The mixture was stirred 
vigorously until starting material was no longer visible via TLC (petroleum ether/EtOAc 7:3). The 
reaction was diluted with CH2Cl2 (20 mL) and washed with saturated aqueous Na2S2O3 (11 mL), H2O (11 
mL), and brine (11 mL). The organic layer was combined, dried (MgSO4) and concentrated under reduced 
pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 3:2) afforded 36 as a 
white solid (0.038 g, 37%): mp 75-77 °C; [α]25D -9.6 (c 0.7, CHCl3); IR (KBr) 3446, 2918, 2850, 1792, 
1652 cm-1: 1H NMR (300 MHz, CDCl3) δ  6.73 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.1 Hz, 1H), 4.01 (s, 1H), 
3.80 (d, J = 7.8 Hz, 1H), 2.20 (t, J = 7.8 Hz, 2H), 1.50 (m, 8H), 1.27 (s, 65H), 0.91 (s, 6H), 0.85 (s, 18H), 
0.22 (s, 3H), 0.22 (s, 3H),  0.07 (s, 3H), 0.06 (s, 3H) 13C NMR (100 MHz, CDCl3) δ 173.0, 169.5, 80.3, 
79.7, 55.4, 51.7, 36.9, 34.8, 32.1, 32.0, 29.9, 29.8, 29.8, 29.7, 29.7, 29.7, 29.6, 29.5, 29.4, 26.5, 26.0, 25.9, 
25.8, 25.8, 25.6, 22.7, 18.2, 18.0, 14.1, -3.9, -4.1, -4.5, -4.7; HRMS (TOF) calcd for C56H116NO5Si2 (M+ + 
H) 938.84. Found 938.8387. 
 
(2S,3R)-3-Benzyloxy-2-(N-tert-butoxycarbonyl)amino-1-octadecanoic acid (38) 
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25) (0.10 g, 0.20 mmol) was 
dissolved in CH2Cl2 (4.4 mL)/H2O (2.2 mL) at rt under N2. TEMPO (0.0060 g, 0.041 mmol) followed by 
BAIB (0.16 g, 0.51 mmol), was added to the reaction flask. The mixture was stirred vigorously until 
starting material was no longer visible via TLC (petroleum ether/EtOAc 7:3). The reaction was diluted 
with CH2Cl2 (20 mL) and washed with saturated aqueous Na2S2O3 (11 mL), H2O (11 mL), and brine (11 
mL). The organic layer was, dried (MgSO4), and concentrated under reduced pressure. Purification by 
flash chromatography on silica gel (CH2Cl2/MeOH 99:1) afforded 38 as a light brown oil (0.083 g, 81%): 
[α]25D -0.3 (c 1.8, CHCl3); IR (KBr) 3432, 2924, 2853, 1717, 1652 cm-1: 1H NMR (300 MHz, CDCl3) δ 
7.22 (m, 5H), 5.15 (s, 1H), 4.62 (d, J
 
= 11.1 Hz, 1H), 4.53 (d, J = 11.1 Hz, 1H), 3.71 (m, 1H), 1.60 (m, 
2H), 1.40 (s, 9H), 1.22 (s, 26H), 0.84 (t, J = 6.9 Hz, 3H) 13C NMR (100 MHz, CDCl3) δ 175.3, 155.9, 
138.1, 128.6, 128.3, 128.0, 80.4, 79.6, 72.3, 32.1, 30.9, 29.9, 29.9, 29.8, 29.8, 29.6, 28.5, 25.9, 22.9, 14.3; 
HRMS (TOF) calcd for C30H52NO5 (M+ + H) 506.3845. Found 506.3887.  
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